Bouche P, Moulonguet A, Younes-Chennoufi A B, Adams D, Baumann N, Meininger V, Léger J M, Said G
Laboratoire d'Explorations Functionelles Neurologie, Hôpital de la Salpêtrieve, Paris, France.
J Neurol Neurosurg Psychiatry. 1995 Jul;59(1):38-44. doi: 10.1136/jnnp.59.1.38.
Twenty four patients with pure motor neuropathy are reported. The chronic motor involvement associated with fasciculations and cramps, mainly in the arms, led, in most patients, to an initial diagnosis of motor neuron disease. In some patients (nine of 24), there was no appreciable muscle atrophy. Tendon reflexes were often absent or weak. The finding of persistent multifocal conduction block confined to motor nerve fibres raises questions about the nature and the importance of this syndrome. Segmental reduction of motor conduction velocity occurred at the site of the block, but significant slowing of motor nerve conduction was not found outside this site. The response to intravenous IVIg treatment seems to be correlated with the absence of amyotrophy. Patients with little or no amyotrophy had an initial and sustained response to IVIg, and did not develop amyotrophy during the follow up study. They could be considered to have a variant of chronic inflammatory demyelinating polyneuropathy. Patients with pronounced amyotrophy independent of the disease duration did not respond as well to IVIg treatment, suggesting the existence of a distinct entity. Among the patients treated about two thirds who had an initial good response to IVIg had high or significant antiganglioside GM1 (anti-GM1) antibody titres, but there was no correlation between the high titres before treatment and long lasting response to IVIg treatment.
本文报告了24例纯运动性神经病患者。慢性运动功能障碍伴有肌束震颤和痉挛,主要累及上肢,多数患者最初被诊断为运动神经元病。部分患者(24例中有9例)无明显肌肉萎缩。腱反射常消失或减弱。局限于运动神经纤维的持续性多灶性传导阻滞的发现,引发了对该综合征本质及重要性的质疑。在传导阻滞部位出现运动传导速度节段性减慢,但在此部位之外未发现运动神经传导显著减慢。静脉注射免疫球蛋白(IVIg)治疗的反应似乎与无肌萎缩相关。几乎没有或没有肌萎缩的患者对IVIg治疗有初始且持续的反应,且在随访研究期间未出现肌萎缩。他们可被视为慢性炎症性脱髓鞘性多发性神经病的一种变异型。无论病程长短,有明显肌萎缩的患者对IVIg治疗反应不佳,提示存在一种独特的疾病实体。在接受治疗的患者中,约三分之二对IVIg初始反应良好的患者抗神经节苷脂GM1(抗GM1)抗体滴度高或显著升高,但治疗前的高滴度与对IVIg治疗的持久反应之间无相关性。